Company intelligence / Profile preview
GlycoMira Therapeutics
Salt Lake City, Utah, United Statesglycomira.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GlycoMira Therapeutics develops a new class of polysaccharide-based drugs that modulate the innate immune system. Their lead candidate, GM‑1111, has shown promising safety and efficacy in preclinical studies targeting solid tumors and supportive care needs such as radiation-induced mucosal injury. The company leverages NIH awards and private investment to advance its programs but has not yet reported late-stage clinical results.[1][4]
- Therapeutic areas
- OncologyPulmonologyGastroenterology
- Modalities
- Polysaccharide-based innate immune modulators[1]Small molecule drug (as per some pipeline listings)[4]
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
National Institutes of Health (grant funding/support)[1]
Beyond the preview
Go deeper on GlycoMira Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoMira Therapeutics.